![Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations | Postgraduate Medical Journal Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations | Postgraduate Medical Journal](https://pmj.bmj.com/content/postgradmedj/90/1067/520/F1.large.jpg)
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations | Postgraduate Medical Journal
![Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease | Circulation Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease | Circulation](https://www.ahajournals.org/cms/asset/0c00a834-7842-4cf0-ac96-6104bf899ad1/2170fig01.jpg)
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease | Circulation
![Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group](https://pharmaceuticalintelligence.files.wordpress.com/2013/09/anticoagulant.jpg)
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
![Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring | Thrombosis Journal | Full Text Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring | Thrombosis Journal | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1477-9560-11-10/MediaObjects/12959_2013_Article_185_Fig1_HTML.jpg)
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring | Thrombosis Journal | Full Text
![Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/newsletters/2017/Oct/images/NOAC_FIG1.png)
Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation
![The Direct Oral Anticoagulants Apixaban, Rivaroxaban, and Edoxaban | American Society for Clinical Laboratory Science The Direct Oral Anticoagulants Apixaban, Rivaroxaban, and Edoxaban | American Society for Clinical Laboratory Science](http://clsjournal.ascls.org/content/ascls/30/1/2/F1.large.jpg)
The Direct Oral Anticoagulants Apixaban, Rivaroxaban, and Edoxaban | American Society for Clinical Laboratory Science
![The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants - ScienceDirect The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0049384810004810-gr1.jpg)